J-106 Immune correlates of HBV cure

Chances for cure in chronic HBV/HDV coinfection

Background Worldwide, chronic infection with HBV and HDV occurs in more than 10 million people with higher rates of developing cirrhosis, hepatic decompensation and hepatocellular carcinoma. Peginterferon (pegIFN) for 48 weeks is one of the current therapies, with poor response rates; prolonging therapy beyond 12 months might be of benefit for the patients. In order to assess the response to a ...

HBV-DNA and primary immune complex glomerulonephritis.

Immune activation, HIV persistence, and the cure.

HIV infection is characterized by persistent immune activation, even in the context of suppressive antiretroviral therapy. This persistent activation, which appears to be fueled by microbial translocation from the gut resulting from HIV-related damage, is associated with deficits in immune function that in turn contribute to persistent activation. The presence of latent HIV reservoirs in lympho...

Kinetics of the immune response during HBV and HCV infection.

The innate immune system has a role not only in protecting the host during the initial period of virus infection, but also in shaping the nature of the adaptive immune response. In this review, we follow the kinetics of the virologic and immunologic events occurring from the time of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. We primarily discuss how the early events after in...

The Role of Immune Cells in Chronic HBV Infection

Hepatitis B virus (HBV) infection is a major cause of chronic liver diseases that may progress to liver cirrhosis and hepatocellular carcinoma. Host immune responses are important factors that determine whether HBV infection is cleared or persists. After infection, viral replication occurs inside hepatocytes, and the secretion of infectious virions can take place at high rates for decades. Cons...